Ilut

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Retrieved on: 
Tuesday, January 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Ilut, New Drug Application, Duane syndrome, Standard of care, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Keratoconus, Corporation, Safety, Dermis, FDA, Pilocarpine, Glaucoma, Eyelid, NYSE, NDA, Food, Patient, GKOS, DED, Eye, Retina, BID, Pharmaceutical industry, 1870 Glaukos

“These clinical updates represent meaningful milestones for two of our key Corneal Health pipeline programs and we look forward to continuing to advance both of these important programs forward in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer.

Key Points: 
  • “These clinical updates represent meaningful milestones for two of our key Corneal Health pipeline programs and we look forward to continuing to advance both of these important programs forward in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • Glaukos plans to randomize approximately 290 subjects in this trial and is targeting enrollment completion by the end of 2023.
  • Glaukos also announced promising topline results from its Phase 2a first-in-human clinical trial for GLK-301 (iLution – Dry Eye Disease (DED)) for the signs and symptoms of DED.
  • Based on these encouraging observations, Glaukos plans to advance GLK-301 into a Phase 2b clinical trial targeted to begin in 2023.

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

Retrieved on: 
Tuesday, January 11, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Patient, Technology, Retina, Elasticity, Eye, Pilocarpine, Cornea, MIGS, SEC, NYSE, Safety, Ageing, Glaucoma surgery, GKOS, U.S. Securities and Exchange Commission, Visual acuity, Presbyopia, Dermis, Corporation, Ilut, Glaucoma, BID, Security (finance), Cross-link, Pharmaceutical industry

The company anticipates it will enroll approximately 120 presbyopic patients in the study across clinical sites in the United States.

Key Points: 
  • The company anticipates it will enroll approximately 120 presbyopic patients in the study across clinical sites in the United States.
  • The dosing of the first patient in the Phase 2 study brings us one step closer to an innovative near vision solution for the millions of patients who suffer from presbyopia.
  • We are privileged to have the opportunity to explore what GLK-302 can do for presbyopic patients in our Phase 2 trial.
  • Presbyopia usually becomes noticeable around the age of 40 and there is no proven way to stop or reverse the progression of presbyopia.

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

Retrieved on: 
Tuesday, January 11, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, DED, Patient, Technology, Retina, Eye, Pilocarpine, Inflammation, Cornea, MIGS, SEC, NYSE, Safety, Glaucoma surgery, GKOS, U.S. Securities and Exchange Commission, Eyelid, Diagnosis, Dermis, Corporation, Ilut, Glaucoma, Duane syndrome, BID, Security (finance), Cross-link, Pharmaceutical industry

The company anticipates it will enroll approximately 200 DED patients in the study across clinical sites in the United States.

Key Points: 
  • The company anticipates it will enroll approximately 200 DED patients in the study across clinical sites in the United States.
  • Additionally, approximately 20 patients with a diagnosis of DED due to Sjogrens Syndrome will also be enrolled.
  • Dry Eye Disease is a common ocular inflammation condition with high unmet clinical need, representing one of the worlds largest ophthalmic markets worldwide.
  • We are delighted to have the opportunity to explore what GLK-301 can do for DED patients in our Phase 2 trial.